NPCi discusses Anticholinergics in COPD
The National Prescribing Centre (NPC) has published a Rapid Review discussing in detail the current concerns about inhaled anticholinergics in people with COPD and an increase in cardiovascular events.
The article details the background to the current concerns, provides a detailed interpretation of the latest information and highlights the limitations in the current data.
Action: Clinicians will find this article useful in reassuring patients. It is thorough and of the usual high standard expected of the NPC.
| « COPD study in the news | Which? Pharmacy Investigation » |
Bookmark in del.icio.us